US 11,879,010 B2
Methods and compositions for pretargeted immunotherapy
Steven Park, Cary, NC (US)
Assigned to The Charlotte Mecklenburg Hospital Authority, Charlotte, NC (US)
Filed by The Charlotte Mecklenburg Hospital Authority, Charlotte, NC (US)
Filed on Sep. 23, 2022, as Appl. No. 17/934,645.
Claims priority of provisional application 63/250,597, filed on Sep. 30, 2021.
Prior Publication US 2023/0101939 A1, Mar. 30, 2023
Int. Cl. C07K 16/22 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01)
CPC C07K 16/22 (2013.01) [C07K 16/2896 (2013.01); C12N 5/0638 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5158 (2013.01); C12N 2510/00 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method of inducing cytotoxicity in a cancer cell in a subject having, suspected of having, or at risk of having cancer, the method comprising:
(a) contacting the cancer cell with a first antibody or fragment thereof, wherein the first antibody or fragment thereof comprises a first antigen binding portion and a targeting ligand and wherein the cancer cell comprises a first antigen on the surface of the cancer cell, under conditions whereby the first antigen binding portion of the first antibody or fragment thereof binds the first antigen on the surface of the cancer cell, wherein the first antigen is CD20, the first antigen binding portion is a CD20 binding portion, and the targeting ligand is tetrazine; and
(b) contacting the cancer cell of step (a) with a natural killer (NK) cell comprising a targeting agent specific for the targeting ligand of the first antibody or fragment thereof, wherein the targeting agent is trans-cyclooctene (TCO) and binds in vivo to the targeting ligand of the first antibody or fragment thereof,
thereby inducing cytotoxicity in the cancer cell.